Antibacterial Activity of Salicylanilide 4-(Trifluoromethyl)benzoates

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F13%3A10145614" target="_blank" >RIV/00216208:11160/13:10145614 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/71009396:_____/13:N0000003

Výsledek na webu

<a href="http://www.mdpi.com/1420-3049/18/4/3674/pdf" target="_blank" >http://www.mdpi.com/1420-3049/18/4/3674/pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/molecules18043674" target="_blank" >10.3390/molecules18043674</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Antibacterial Activity of Salicylanilide 4-(Trifluoromethyl)benzoates

Popis výsledku v původním jazyce

The development of novel antimicrobial agents represents a timely research topic. Eighteen salicylanilide 4-(trifluoromethyl)benzoates were evaluated against Mycobacterium tuberculosis, M. avium and M. kansasii, eight bacterial strains including methicillin-resistant Staphylococcus aureus (MRSA) and for the inhibition of mycobacterial isocitrate lyase. Some compounds were further screened against drug-resistant M. tuberculosis and for their cytotoxicity. Minimum inhibitory concentrations (MICs) for allmycobacterial strains were within 0.5-32 mu mol/L, with 4-chloro-2-[4-(trifluoromethyl)phenylcarbamoyl] phenyl 4-(trifluoromethyl) benzoate superiority. Grampositive bacteria including MRSA were inhibited with MICs }= 0.49 mu mol/L, while Gram-negative ones were much less susceptible. Salicylanilide 4-(trifluoromethyl) benzoates showed significant antibacterial properties, for many strains being comparable to standard drugs (isoniazid, benzylpenicillin) with no cross-resistance. All este

Název v anglickém jazyce

Antibacterial Activity of Salicylanilide 4-(Trifluoromethyl)benzoates

Popis výsledku anglicky

The development of novel antimicrobial agents represents a timely research topic. Eighteen salicylanilide 4-(trifluoromethyl)benzoates were evaluated against Mycobacterium tuberculosis, M. avium and M. kansasii, eight bacterial strains including methicillin-resistant Staphylococcus aureus (MRSA) and for the inhibition of mycobacterial isocitrate lyase. Some compounds were further screened against drug-resistant M. tuberculosis and for their cytotoxicity. Minimum inhibitory concentrations (MICs) for allmycobacterial strains were within 0.5-32 mu mol/L, with 4-chloro-2-[4-(trifluoromethyl)phenylcarbamoyl] phenyl 4-(trifluoromethyl) benzoate superiority. Grampositive bacteria including MRSA were inhibited with MICs }= 0.49 mu mol/L, while Gram-negative ones were much less susceptible. Salicylanilide 4-(trifluoromethyl) benzoates showed significant antibacterial properties, for many strains being comparable to standard drugs (isoniazid, benzylpenicillin) with no cross-resistance. All este

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecules

ISSN

1420-3049

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

15

Strana od-do

3674-3688

Kód UT WoS článku

000318020100002

EID výsledku v databázi Scopus

—